-
Cell and Gene Therapy Manufacturing: Operational Challenges and Strategic Considerations
Neeta Ratanghayra
December 20, 2024
Producing CGTs requires highly specialized infrastructure, precise processes, and significant investments, making the manufacturing landscape both complex and costly.
-
Decoding the Role of Synthetic Biology in Pharmaceuticals
Neeta Ratanghayra
October 16, 2024
Recognized for its transformative potential, synthetic biology has emerged as a technology poised to revolutionize various industries, including pharmaceuticals.
-
Navigating the Landscape of Rare Diseases: Current Trends and Future Perspectives
Neeta Ratanghayra
September 29, 2024
Rising Investment and Market Dynamics, Future Perspectives in the Orphan Drug Market and The Scenario in China.
-
Immuno-Oncology: Current Market Landscape and Future Trends(1)
Neeta Ratanghayra
September 18, 2024
Immune Checkpoint Inhibitors & Challenges and Future Directions.
-
Gut Hormone-Based Pharmacotherapies for Obesity
Neeta Ratanghayra
April 28, 2024
The history of pharmacotherapy for obesity is marked by a series of promising drugs that were withdrawn due to safety concerns.
-
The Evolving Landscape of Heart Failure Therapies
Neeta Ratanghayra
January 31, 2024
Heart failure (HF) is a leading cause of disability worldwide and has a major impact on the global economy and healthcare systems.
-
What's happening in HF therapies
Neeta Ratanghayra
January 02, 2024
Heart failure (HF) is a leading cause of disability worldwide and has a major impact on the global economy and healthcare systems.The severity of the disease warrants the development of innovative solutions to address the current treatment gap.
-
Antibody-Drug Conjugates - Lessons Learned
Neeta Ratanghayra
May 20, 2022
Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future.
-
Trends and Developments in HIV Research
Neeta Ratanghayra
March 30, 2022
Novel treatment strategies and advances in care have transformed the lives of people living with HIV (human immunodeficiency virus). Antiretroviral therapy (ART), once-daily single-tablet regimens (STRs)...
-
Bispecific Antibodies – Key Developments in China
Neeta Ratanghayra
August 06, 2021
Bispecific antibodies (BsAbs) are artificially designed antibodies with dual binding sites. The binding sites may be directed at two different antigens or two different epitopes on the same antigen.